Kannan R. Karukurichi

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Loren Lasko, Clarissa G. Jakob, Rohinton Edalji et al. · Nature · 2017 · 813 citations · Full text

Lineage-specific Tumours, Medicine, Immune Checkpoint Inhibitor +8

α-Vinylic amino acids: occurrence, asymmetric synthesis, and biochemical mechanisms

David B. Berkowitz, Bradley D. Charette, Kannan R. Karukurichi et al. · Tetrahedron Asymmetry · 2006 · 106 citations

Natural Product Synthesis, α-Vinylic Amino Acids, Biochemistry

Use of fluorinated functionality in enzyme inhibitor development: Mechanistic and analytical advantages

David B. Berkowitz, Kannan R. Karukurichi, Roberto de la Salud‐Bea et al. · Journal of Fluorine Chemistry · 2008 · 91 citations

Enzyme Inhibitor Development, Medicinal Chemistry, Biochemistry +10

Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases

Michael R. Michaelides, Arthur F. Kluge, Michael A. Patane et al. · ACS Medicinal Chemistry Letters · 2017 · 72 citations · Full text

Double-Cuvette ISES:  In Situ Estimation of Enantioselectivity and Relative Rate for Catalyst Screening

Sangeeta Dey, Kannan R. Karukurichi, Weijun Shen et al. · Journal of the American Chemical Society · 2005 · 48 citations

Situ Estimation, Engineering, Organic Chemistry +16